
Shares in Sartorius SATG.DE jump around 10% to May highs after the German pharmaceutical equipment supplier reported Q4 earnings beat and strong BPS orders
Q4 underlying EBITDA came in at 259 million, 5% above beat Vara consensus cited by J.P.Morgan
JPM also cites strong Bioprocess Solutions (BPS) orders at 856.7 million euros, 22% ahead of the brokerage's estimates
Its French subsidiary Sartorius Stedim Biotech STDM.PA jumps around 12%, with JPM also noting a 3% beat on underlying EBITDA
Sartorius' stock is among top performers of the German blue-chip index .GDAXI, and both Sartorius and Sartorius Stedim Biotech are at the top of STOXX 600 .STOXX index